Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

In situ RAS:RAF binding correlates with response to KRAS^G12C inhibitors in KRAS^G12C-mutant non–small cell lung cancer

Ryoji Kato, Hitendra S. Solanki, Hilal Ozakinci, Bina Desai, Harika Gundlapalli, Yu Chi Yang, Ida Aronchik, Mallika Singh, Joseph Johnson, Andriy Marusyk, Theresa A. Boyle, Eric B. Haura

Clin Cancer Res (2025)

https://doi.org/10.1158/1078-0432.CCR-24-3714

Published: 21 January 2025

View article titled, In situ RAS:RAF binding correlates with response to KRASG12C inhibitors in KRASG12C-mutant non–small cell lung cancer

Includes: Supplementary data

Journal Articles

Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Alberto A. Chiappori, Ben Creelan, Tawee Tanvetyanon, Jhanelle E. Gray, Eric B. Haura, Ram Thapa, Margaret L. Barlow, Zhihua Chen, Dung Tsa Chen, Amer A. Beg, Theresa A. Boyle, Julio Castro, Liza Morgan, Erick Morris, Mehreteab Aregay, Felipe K. Hurtado, Luigi Manenti, Scott Antonia

Clin Cancer Res (2022) 28 (11): 2313–2320.

https://doi.org/10.1158/1078-0432.CCR-21-2742

Published: 01 June 2022

View article titled, Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Includes: Supplementary data

Journal Articles

Cell Type–specific Adaptive Signaling Responses to KRAS^G12C Inhibition

Hitendra S. Solanki, Eric A. Welsh, Bin Fang, Victoria Izumi, Lancia Darville, Brandon Stone, Ryan Franzese, Sandip Chavan, Fumi Kinose, Denis Imbody, John M. Koomen, Uwe Rix, Eric B. Haura

Clin Cancer Res (2021) 27 (9): 2533–2548.

https://doi.org/10.1158/1078-0432.CCR-20-3872

Published: 01 May 2021

View article titled, Cell Type–specific Adaptive Signaling Responses to KRASG12C Inhibition

Includes: Supplementary data

Journal Articles

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Clin Cancer Res (2021) 27 (6): 1604–1611.

https://doi.org/10.1158/1078-0432.CCR-20-4084

Published: 15 March 2021

View article titled, Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Includes: Supplementary data

Journal Articles

Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Jhanelle E. Gray, Andreas Saltos, Tawee Tanvetyanon, Eric B. Haura, Ben Creelan, Scott J. Antonia, Michael Shafique, Hong Zheng, Wenjie Dai, James J. Saller, Zhihua Chen, Nishan Tchekmedyian, Kristen Goas, Ram Thapa, Theresa A. Boyle, Dung-Tsa Chen, Amer A. Beg

Clin Cancer Res (2019) 25 (22): 6623–6632.

https://doi.org/10.1158/1078-0432.CCR-19-1305

Published: 15 November 2019

View article titled, Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Includes: Supplementary data

Journal Articles

Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium

Clin Cancer Res (2017) 23 (24): 7550–7557.

https://doi.org/10.1158/1078-0432.CCR-17-1401

Published: 14 December 2017

View article titled, Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium

Includes: Supplementary data

Journal Articles

MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors

Matthew A. Smith, Thomas Licata, Aliya Lakhani, Marileila Varella Garcia, Hans-Ulrich Schildhaus, Vincent Vuaroqueaux, Balazs Halmos, Alain C. Borczuk, Y. Ann Chen, Benjamin C. Creelan, Theresa A. Boyle, Eric B. Haura

Clin Cancer Res (2017) 23 (22): 7084–7096.

https://doi.org/10.1158/1078-0432.CCR-16-3006

Published: 14 November 2017

View article titled, MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors

Includes: Supplementary data

Journal Articles

Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry–Based Phosphotyrosine Proteomics

Scott M. Haake, Jiannong Li, Yun Bai, Fumi Kinose, Bin Fang, Eric A. Welsh, Roy Zent, Jasreman Dhillon, Julio M. Pow-Sang, Y. Ann Chen, John M. Koomen, W. Kimryn Rathmell, Mayer Fishman, Eric B. Haura

Clin Cancer Res (2016) 22 (22): 5605–5616.

https://doi.org/10.1158/1078-0432.CCR-15-1673

Published: 14 November 2016

View article titled, Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry–Based Phosphotyrosine Proteomics

Includes: Supplementary data

Journal Articles

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

Hong Zheng, Weipeng Zhao, Cihui Yan, Crystina C. Watson, Michael Massengill, Mengyu Xie, Chris Massengill, David R. Noyes, Gary V. Martinez, Roha Afzal, Zhihua Chen, Xiubao Ren, Scott J. Antonia, Eric B. Haura, Brian Ruffell, Amer A. Beg

Clin Cancer Res (2016) 22 (16): 4119–4132.

https://doi.org/10.1158/1078-0432.CCR-15-2584

Published: 14 August 2016

View article titled, HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

Includes: Supplementary data

Journal Articles

Abstract B54: Characterizing pathway vulnerabilities and tumor heterogeneity through signaling-associated complexes

Matthew A. Smith, Leah Clark, Richard Hall, Kate Fisher, Takeshi Yoshida, Vincent Vuaroqueaux, Heinz-Herbert Fiebig, Ann Chen, Eric B. Haura

Clin Cancer Res (2015) 21 (4_Supplement): B54.

https://doi.org/10.1158/1557-3265.PMS14-B54

Published: 13 February 2015

View article titled, Abstract B54: Characterizing pathway vulnerabilities and tumor heterogeneity through signaling-associated complexes

Journal Articles

Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer

Takeshi Yoshida, Guolin Zhang, Matthew A. Smith, Alex S. Lopez, Yun Bai, Jiannong Li, Bin Fang, John Koomen, Bhupendra Rawal, Kate J. Fisher, Ann Y. Chen, Michiko Kitano, Yume Morita, Haruka Yamaguchi, Kiyoko Shibata, Takafumi Okabe, Isamu Okamoto, Kazuhiko Nakagawa, Eric B. Haura

Clin Cancer Res (2014) 20 (15): 4059–4074.

https://doi.org/10.1158/1078-0432.CCR-13-1559

Published: 31 July 2014

View article titled, Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer

Includes: Supplementary data

Journal Articles

Abstract A07: MTI-101 induces synergistic cell kill in combination with Erlotinib in EGFR-driven lung cancer models.

Lisa E. Blumencranz, Rajesh R. Nair, Mark L. McLaughlin, Eric B. Haura, Lori A. Hazlehurst

Clin Cancer Res (2014) 20 (2_Supplement): A07.

https://doi.org/10.1158/1078-0432.14AACRIASLC-A07

Published: 16 January 2014

View article titled, Abstract A07: MTI-101 induces synergistic cell kill in combination with Erlotinib in EGFR-driven lung cancer models.

Journal Articles

Abstract IA2: Network models in oncogene-addicted lung cancer

Eric B. Haura, Takeshi Yoshida, Bin Fang, Alexey Stukalov, Steven Eschrich, Eric Welsh, Jacques Colinge, John Koomen, Giulio Superti-Furga, Jiannong Li, Uwe Rix, Guolin Zhang, Jae-Young Kim, Keiryn Bennett, Lanxi Song, Ann Chen, Yun Bai

Clin Cancer Res (2012) 18 (3_Supplement): IA2.

https://doi.org/10.1158/1078-0432.12AACRIASLC-IA2

Published: 01 February 2012

View article titled, Abstract IA2: Network models in oncogene-addicted lung cancer

Journal Articles

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

Eric B. Haura, Alejandro D. Ricart, Timothy G. Larson, Philip J. Stella, Lyudmila Bazhenova, Vincent A. Miller, Roger B. Cohen, Peter D. Eisenberg, Paulina Selaru, Keith D. Wilner, Shirish M. Gadgeel

Clin Cancer Res (2010) 16 (8): 2450–2457.

https://doi.org/10.1158/1078-0432.CCR-09-1920

Published: 14 April 2010

View article titled, A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

Journal Articles

Activated Epidermal Growth Factor Receptor–Stat-3 Signaling Promotes Tumor Survival In vivo in Non–Small Cell Lung Cancer

Eric B. Haura, Zhong Zheng, Lanxi Song, Alan Cantor, Gerold Bepler

Clin Cancer Res (2005) 11 (23): 8288–8294.

https://doi.org/10.1158/1078-0432.CCR-05-0827

Published: 01 December 2005

View article titled, Activated Epidermal Growth Factor Receptor–Stat-3 Signaling Promotes Tumor Survival In vivo in Non–Small Cell Lung Cancer

NARROW

In situ RAS:RAF binding correlates with response to KRAS^G12C inhibitors in KRAS^G12C-mutant non–small cell lung cancer

Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Cell Type–specific Adaptive Signaling Responses to KRAS^G12C Inhibition

Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903)

Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer

Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium

MET–GRB2 Signaling-Associated Complexes Correlate with Oncogenic MET Signaling and Sensitivity to MET Kinase Inhibitors

Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry–Based Phosphotyrosine Proteomics

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

Abstract B54: Characterizing pathway vulnerabilities and tumor heterogeneity through signaling-associated complexes

Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non–Small Cell Lung Cancer

Abstract A07: MTI-101 induces synergistic cell kill in combination with Erlotinib in EGFR-driven lung cancer models.

Abstract IA2: Network models in oncogene-addicted lung cancer

A Phase II Study of PD-0325901, an Oral MEK Inhibitor, in Previously Treated Patients with Advanced Non–Small Cell Lung Cancer

Activated Epidermal Growth Factor Receptor–Stat-3 Signaling Promotes Tumor Survival In vivo in Non–Small Cell Lung Cancer

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only